Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

ded December 31, 2007, the Company reported a net loss of $23.3 million, or $0.79 per share, compared with a net loss of $56.8 million, or $2.52 per share, for the year ended December 31, 2006. (All share and per-share data have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.)

Net product sales of $0.3 million for the fourth quarter of 2007 increased from $0.1 million for the fourth quarter of 2006, primarily due to a reduction in a provision for sales returns of Ganite(R) of $0.1 million. Net product sales for the year ended December 31, 2007 of $0.6 million declined from the prior-year period of $0.7 million as product sales in 2007 and 2006 included favorable adjustments to a reserve for returns of Ganite of $0.1 million and $0.3 million, respectively. Operating expenses for the fourth quarter and the year ended December 31, 2007 declined from their comparable prior-year periods, as the prior year included a buildup of sales, marketing and manufacturing expenses incurred in preparation for a possible commercial launch of Genasense. In addition, lower expenses in 2007 reflect the impact of a staff reduction in December 2006.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provided for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At December 31, 2007, the revised estimated value of the common shares portion of the litigation settlement is $1.0 million based on a closing price of Genta's common stock of $0.52 per share, resulting in a reduction in the provision of $1.6 million and $4.2 million for the fourth quarter and year ended December 31, 2007, respectively.

Also in the fourth quarter of 2006, we accounted for the impairment of prepaid royalties and recorded a write-off of this asset of $1.3 million due to the non-approvabl
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip.  Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... AMSTERDAM, September 19, 2011 Agendia, ... that a published report highlighting the development and ... was published online in Breast Cancer Research ... a part of Agendia,s Symphony™ suite of breast ...
... Laser Med Center , which specializes in treating Trigeminal ... laser device. This is a non-invasive alternative to surgery, ... Trigeminal Neuralgia is a terribly painful condition of ... (the fifth cranial nerve or CN5) is primarily a ...
Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment 2
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 TheBeautyPlace.com ... Nioxin. Pattern hair loss is not a result of ... According to Men’s Fitness Magazine, 70% of men suffer ... Professional Strength is renowned for hair transplant surgery, ... fights male pattern baldness known as Bosley Professional Strength. ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... continue to mount in courts throughout the country, Bernstein ... that metal-on-metal hip replacement patients often suffer tissue damage ... During the study, which according to Science Daily will ... 69 metal-on-metal hip replacement recipients underwent MRI screens of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... every patient in Sweden having percutaneous coronary intervention ... coronary artery disease- has found that PCI implantations ... associated with lower rates of relapse (restenosis), stent ... stents and bare-metal stents.(1) The findings, from ...
... diagnosed with diabetes and hypertension have time to try ... without medications, but not too much time. ... to a year were smalla two-day reduction in quality-adjusted ... researchers published online for the Journal of General ...
... (HealthDay News) -- Inflammatory bowel disease (IBD) is becoming more ... Researchers who analyzed data from all population-based studies about the ... new cases is increasing or stable in virtually every region ... had the highest number of cases, while Asia had a ...
... There,s new evidence that annual prostate cancer screening does not ... 50s and 60s and those with underlying health conditions, according ... in St. Louis. A longer follow-up of more than ... years of aggressive, annual screening for prostate cancer led to ...
... doesn,t affect the quantity (or value) of imaging services received ... study in the January issue of the Journal of ... 51 million Americans, or 16.7 percent of the population, were ... of insurance is associated with less preventive care, delays in ...
... By Alan Mozes HealthDay Reporter , FRIDAY, Jan. ... to different people -- for some, anxiety and paranoia can ... a unique brain scan study suggests two ingredients in pot ... who watched the effects of the two marijuana ingredients -- ...
Cached Medicine News:Health News:New 'real-world' reassuring data from the SCAAR registry 2Health News:New 'real-world' reassuring data from the SCAAR registry 3Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:As Nations Develop, So May Bowel Disease 2Health News:Mass prostate cancer screening doesn't reduce deaths 2Health News:Mass prostate cancer screening doesn't reduce deaths 3Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 2Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 3
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
... for temporary internal drainage from the ureteropelvic ... a stricture. The segment with no sideports ... while preventing ingrowth of the ureteral wall ... packages. Intended for one-time use. CAUTION: Periodic ...
ACMI™ 4.8 Fr Closed Tip Ureteral Stents are easily inserted through the 5 Fr working port of an endoscope. Large internal lumens enhance urinary flow, promoting the kind of drainage you might o...
... Used for retrograde ... and subsequent ureteral stent ... has a radiopaque band ... to aid in fluoroscopic ...
Medicine Products: